TMP/SMX vs placebo, no treatment or non‐PCP drug
Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).
1 finding from 1 review
- Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients 2014 · Cochrane Headline outcomes onlyRR 0.28 [0.05, 1.7]5 studies · 530 participantsModerate